胸苷酸合成酶是肝动脉灌注化疗中反应和耐药性的预测指标。
Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy.
作者信息
Kornmann M, Link K H, Lenz H J, Pillasch J, Metzger R, Butzer U, Leder G H, Weindel M, Safi F, Danenberg K D, Beger H G, Danenberg P V
机构信息
Department of General Surgery, University of Ulm, Germany.
出版信息
Cancer Lett. 1997 Sep 16;118(1):29-35. doi: 10.1016/s0304-3835(97)00220-6.
The value of intratumoral thymidylate synthase (TS) quantitation as a predictive parameter for hepatic artery infusion (HAI) chemotherapy in patients with colorectal liver metastases was investigated. Relative TS mRNA levels were determined in 29 tumor samples using a quantitative RT-PCR amplification method. The median level of expression was 3.0 x 10(-3) (no units) and varied considerably among the tumors over a range of 135-fold. Patients with low TS levels were 4.1-fold more likely to respond (P < 0.03) compared to patients with high TS levels. Our results indicate that TS quantitation is a valuable predictive marker for tumor response to HAI therapy.
研究了瘤内胸苷酸合成酶（TS）定量作为结直肠癌肝转移患者肝动脉灌注（HAI）化疗预测参数的价值。使用定量逆转录聚合酶链反应（RT-PCR）扩增方法测定了29个肿瘤样本中的相对TS mRNA水平。表达的中位数水平为3.0×10⁻³（无单位），在肿瘤之间变化很大，范围达135倍。与TS水平高的患者相比，TS水平低的患者反应可能性高4.1倍（P < 0.03）。我们的结果表明，TS定量是肿瘤对HAI治疗反应的有价值预测标志物。
Zotero 插件